Press Releases
MAPS PBC Announces Frontiers in Psychiatry Published First Study to Evaluate Neural Impact of MDMA-Assisted Therapy in Patients with PTSD
Results demonstrate a biological correlation between reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders Study sheds light on neurological mechanisms that drive MDMA-assisted therapy in PTSD SAN JOSE, Calif.,...
MAPS PBC Announces Positive Results from Confirmatory Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
Results met study pre-specified primary and key secondary endpoints and will support new drug application submission expected in third quarter of 2023 No serious adverse events observed in the MDMA group If approved, MAPS PBC’s MDMA-assisted therapy could be the...
MAPS PBC Completes Second Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
Top-line data expected in the first quarter of 2023 Data to be part of new drug application submission expected in third quarter of 2023 SAN JOSE, Calif., November 17, 2022—MAPS Public Benefit Corporation (“MAPS PBC”), a private company dedicated to the development...
MAPS PBC Elects Jeff George as Chairman of the Board of Directors
The new chairman brings critical commercial expertise and pharmaceutical leadership needed during MAPS PBC’s growth phase MDMA-assisted therapy, a novel treatment for post-traumatic stress disorder (PTSD) with FDA breakthrough therapy designation, is on track for new...
MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations
The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care System This essential proof-of-principle study tests safety and...
Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated Therapy for PTSD will be completed in late 2022, with a targeted...
MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors
Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board MDMA-assisted therapy, a novel treatment for PTSD with FDA...
MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on schedule supports targeted submission of the New Drug Application...
Michael Mullette Joins MAPS PBC Senior Leadership as Chief Operating Officer
Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA Hire represents a major step forward in...
MAPS PBC Adopts Charter for Independent Ethics Review Board
FOR IMMEDIATE RELEASE Independent members will inform continual iteration and improvement of ethical governance of MDMA-assisted therapy research and therapist training program Independent Ethical Review Board engages outside experts to provide additional layer of...